Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, underscoring the company's financial strength and operational efficiency.
The revolving credit facility remains available, providing borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions. This continued access to capital supports Knight's ongoing growth strategy across its pan-American pharmaceutical business. The repayment reduces interest expenses and strengthens the company's balance sheet, positioning it for future investments and acquisitions.
Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD. For more information, visit www.knighttx.com.
The news of the repayment is significant as it demonstrates Knight's ability to generate robust cash flows and manage debt effectively. This financial discipline enhances investor confidence and provides flexibility for future growth initiatives. The full press release is available at https://ibn.fm/8eluB.
